-+ 0.00%
-+ 0.00%
-+ 0.00%

NovaBridge’s Subsidiary Visara Doses First Patient In ASCEND Study, Randomized Phase 2b Trial To Evaluate VIS-101 In Patients With Wet Age-Related Macular Degeneration

Benzinga·11/18/2026 12:10:08
Diffusion vocale

Head-to-head trial designed to evaluate VIS-101’s potential for sustained disease control with extended treatment intervals

Phase 2a results showed approximately 50% of patients in the 6 mg treatment-naïve cohort remained retreatment-free six months after the last loading dose

ROCKVILLE, Md., Nov. 18, 2026 (GLOBE NEWSWIRE) -- Visara, Inc. ("Visara"), a majority-owned ophthalmology subsidiary of NovaBridge Biosciences, Inc. ("NovaBridge") (NASDAQ:NBP), today announced that the first patient has been dosed in its ASCEND study, a randomized Phase 2b trial designed to evaluate the efficacy, safety and durability of VIS-101, including its potential to enable extended treatment intervals after monthly loading doses, in patients with wet age-related macular degeneration ("wet AMD"). The approximately 244-patient study is evaluating two doses of VIS-101 (6 mg and 9 mg) head-to-head against 2 mg aflibercept and is being conducted in China in partnership with Everest Medicines (HKEX 1952.HK).

VIS-101 is a tetravalent, dual vascular endothelial growth factor ("VEGF")-A and angiopoietin-2 ("ANG-2") inhibitor, purpose-designed to have best-in-class efficacy and durability. VIS-101 is in development for retinal vascular diseases, including wet AMD, diabetic macular edema (DME) and retinal vein occlusion (RVO). In the randomized, dose ranging Phase 2a study, VIS-101 demonstrated rapid, robust, and durable treatment responses in wet AMD, along with a favorable safety profile. Approximately 50% of patients in the 6 mg treatment-naïve cohort remained retreatment-free six months after the last loading dose, supporting VIS-101’s potential for best-in-class durability.